Fig. 4
From: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy
Growth of resistant subclones during therapy. a The change in overall tumor size (blue) and resistant subclone size (red) is shown for P1 and P5, assuming exponential growth and clonal replacement. Across a range of feasible growth rates, the resistant subclone was prevalent in the pre-treatment tumor. b In P5, a subset of mutations that were clonal in the post-treatment tumor sample were present at low frequency in the pre-treatment tumor sample (red oval). CCF cancer cell fraction. c Schematic for clonal replacement in P1 and P5, where width of the schematic over time corresponds to the logarithm of the number of tumor cells. Aberrations present in each subclone are listed: grey is truncal, green is the resistant subclone that replaces the tumor, and blue, red, and purple are subclones within the resistant subclone that become detectable post-treatment. Source data for panel b are provided as a Source Data file
